Also known as: Janux
Janux Therapeutics is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer and autoimmune diseases. Its pipeline includes JANX007, JANX008, and JANX011 built on TRACTr, TRACIr, and ARM platforms.
Janux Therapeutics has dosed the first participant in a Phase 1 clinical trial of JANX011, a CD19-targeted bispecific candidate designed using its ARM platform for autoimmune disease treatment.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
